Revista Cubana de Farmacia
versão On-line ISSN 1561-2988
RUBIO HERNANDEZ, Luis Alberto et al. Factores de riesgo en el uso de los aminoglucósidos en pacientes oncológicos. Rev Cubana Farm [online]. 2002, vol.36, n.2, pp. 93-99. ISSN 1561-2988.
The objectives of this paper were to observe the behavior of risk factors that might unfavorably affect the response of patients to treatment with aminoglycosides, to determine the frequency of indication of serum creatinine test, to assess the dosage level and to detect potential drug interactions in drug-therapeutic profiles. A retrospective study, which comprised 157 cases selected from oncological patients admitted to the National Institute of Oncology and Radiobiology was conducted. These patients were indistinctively prescribed amykacin, gentamicin and kanamycin. Necessary data for research were taken from medical histories and data collection forms were designed. The risk factors of higher incidence were age over 59 years (45,9%), major surgery 72 hours before treatment (45,2%), potential drug interactions (42%), smoking (40,7%), renal failure (32,5%) and recent nephrotoxics (35%). Each of these percentages is related to the whole sample. Those patients with two or more risk factors predominated (83%). Serum creatinine test was indicated in 98 patients (62,4%). It is necessary to underline that this biological indicator, a very important one for assessing the kidney functioning, was only measured in 38 patients for seven days before the treatment with aminoglycosides, which represents 24% of the whole sample. Dosage level could only be evaluated in 21% of the whole sample due to the lack of basic elements such as serum creatinine, weight and height. Potential drug interactions produced by aminoglycosides were detected in 41% of patients; the highest frequency of these interactions was found in betalactams (37%).
Palavras-chave : RISK FACTORS; ANTIBIOTICS, AMINOGLYCOSIDES [adverse effects]; ANTIOBIOTICS AMINOGLYCOSIDES [therapeutic use]; NEOPLASMS [drug therapy]; AMIKACIN [adverse effects]; GENTAMICINS [adverse effects]; KANAMYCIN [adverse effects].